Published Online
on May 1, 2006

A more recent version of this article appeared on May 9, 2006

This Article Full Text (PDF) Data Supplement All Versions of this Article: 113/18/2211    most recent CIRCULATIONAHA.105.560250v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, K. Articles by Ng, P. C. Search for Related Content PubMed PubMed Citation Articles by Li, K. Articles by Ng, P. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Hazardous Substances DB DOXORUBICIN Related Collections Other heart failure Animal models of human disease Other Treatment

Submitted on October 3, 2005
Revised on March 8, 2006
Accepted on March 9, 2006

Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin

Karen Li PhD, Rita Yn Tz Sung MD^*, Wei Zhe Huang MD, Mo Yang MD, PhD, Nga Hin Pong MD, MPhil, Shuk Man Lee MPhil, Wood Yee Chan PhD, Hailu Zhao MD, Man Yin To BSc, Tai Fai Fok MD, Chi Kong Li MD, Yuek Oi Wong PhD, and Pak Cheung Ng MD

From the Departments of Pediatrics (K.L., R.Y.T.S., M.Y., N.H.P., S.M.L., M.Y.T., T.F.F., C.K.L., Y.O.W., P.C.N.), Anatomy (W.Y.C.), and Medicine and Therapeutics (H.Z.), The Chinese University of Hong Kong, Shatin, NT, Hong Kong; and Department of Cardiac Pulmonary Surgery, Shantou University, Shantou, China (W.Z.H.).

^* To whom correspondence should be addressed. E-mail: yntzsung{at}cuhk.edu.hk.

Background--Doxorubicin (DOX) is an important antineoplastic agent. However, the associated cardiotoxicity, possibly mediated by the production of reactive oxygen species, has remained a significant and dose-limiting clinical problem. Our hypothesis is that the hematopoietic/megakaryocytopoietic growth factor thrombopoietin (TPO) protects against DOX-induced cardiotoxicity and might involve antiapoptotic mechanism exerted on cardiomyocytes.

Methods and Results--In vitro investigations on H9C2 cell line and spontaneously beating cells of primary, neonatal rat ventricle, as well as an in vivo study in a mouse model of DOX-induced acute cardiomyopathy, were performed. Our results showed that pretreatment with TPO significantly increased viability of DOX-injured H9C2 cells and beating rates of neonatal myocytes, with effects similar to those of dexrazoxane, a clinically approved cardiac protective agent. TPO ameliorated DOX-induced apoptosis of H9C2 cells as demonstrated by assays of annexin V, active caspase-3, and mitochondrial membrane potential. In the mouse model, administration of TPO (12.5 µg/kg IP for 3 alternate days) significantly reduced DOX-induced (20 mg/kg) cardiotoxicity, including low blood cell count, cardiomyocyte lesions (apoptosis, vacuolization, and myofibrillar loss), and animal mortality. Using Doppler echocardiography, we observed increased heart rate, fractional shortening, and cardiac output in animals pretreated with TPO compared with those receiving DOX alone.

Conclusions--These data have provided the first evidence that TPO is a protective agent against DOX-induced cardiac injury. We propose to further explore an integrated program, incorporating TPO with other protocols, for treatment of DOX-induced cardiotoxicity and other forms of cardiomyopathy.

Key words: apoptosis • cardiomyopathy • doxorubicin • echocardiography • thrombopoietin

This article has been cited by other articles:

				P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1466 - H1483. [Abstract] [Full Text] [PDF]

				Y. Hiraumi, E. Iwai-Kanai, S. Baba, Y. Yui, Y. Kamitsuji, Y. Mizushima, H. Matsubara, M. Watanabe, K.-i. Watanabe, S. Toyokuni, et al. Granulocyte colony-stimulating factor protects cardiac mitochondria in the early phase of cardiac injury Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H823 - H832. [Abstract] [Full Text] [PDF]

				W. Zhu, M. H. Soonpaa, H. Chen, W. Shen, R. M. Payne, E. A. Liechty, R. L. Caldwell, W. Shou, and L. J. Field Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway Circulation, January 6, 2009; 119(1): 99 - 106. [Abstract] [Full Text] [PDF]

				H. J. Choi, M. R. Seon, S. S. Lim, J.-S. Kim, H. S. Chun, and J. H. Y. Park Hexane/Ethanol Extract of Glycyrrhiza uralensis Licorice Suppresses Doxorubicin-Induced Apoptosis in H9c2 Rat Cardiac Myoblasts Experimental Biology and Medicine, December 1, 2008; 233(12): 1554 - 1560. [Abstract] [Full Text] [PDF]

				C. D. Venkatakrishnan, K. Dunsmore, H. Wong, S. Roy, C. K. Sen, A. Wani, J. L. Zweier, and G. Ilangovan HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1736 - H1744. [Abstract] [Full Text] [PDF]

				J. W. Calvert and D. J. Lefer Thrombopoietin emerges as a new haematopoietic cytokine that confers cardioprotection against acute myocardial infarction Cardiovasc Res, January 1, 2008; 77(1): 2 - 3. [Full Text] [PDF]

				J. E. Baker, J. Su, A. Hsu, Y. Shi, M. Zhao, J. L. Strande, X. Fu, H. Xu, A. Eis, R. Komorowski, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats Cardiovasc Res, January 1, 2008; 77(1): 44 - 53. [Abstract] [Full Text] [PDF]

				S. Turakhia, C. D. Venkatakrishnan, K. Dunsmore, H. Wong, P. Kuppusamy, J. L. Zweier, and G. Ilangovan Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27 Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3111 - H3121. [Abstract] [Full Text] [PDF]

				P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N. P. Gerard, L. Liaudet, G. Kunos, et al. Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity J. Am. Coll. Cardiol., August 7, 2007; 50(6): 528 - 536. [Abstract] [Full Text] [PDF]

				N. M. Kogan, M. Schlesinger, M. Peters, G. Marincheva, R. Beeri, and R. Mechoulam A Cannabinoid Anticancer Quinone, HU-331, Is More Potent and Less Cardiotoxic Than Doxorubicin: A Comparative in Vivo Study J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 646 - 653. [Abstract] [Full Text] [PDF]

				C. B. Granger Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy: Can It Be Done? Circulation, December 5, 2006; 114(23): 2432 - 2433. [Full Text] [PDF]